Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...

Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies ...

MJH Life Sciences’ acquisition of BPD Healthcare represents a major expansion of strategic capabilities for MJH across ...

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to ...

Innovent Biologics and Takeda announced a strategic global collaboration aiming to advance next-generation IO and ADC cancer ...

Novo Nordisk's board changes stem from disagreements with the Novo Nordisk Foundation over board composition and strategic ...

The solution lies in flexibility. Sites need to be able to work in whatever formats make sense for them, whether that’s a ...

mRNA-based COVID vaccines significantly improve survival rates in cancer patients undergoing immunotherapy, particularly in ...

Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices? Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what ...

MJH has grown quickly in recent years, expanding both its reach and scope in the healthcare space. In 2019, the company ...

Many of the biodiversity risks associated with pharmaceutical production occur beyond the direct operational control of pharmaceutical businesses, whic means that addressing them requires a ...

Pharmaceutical Executive: What impact will TrumpRx and other DTC programs have on drug availability? Jesse Mendelsohn: To be ...